Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
12.10 x 1 12.25 x 1
Post-market by (Cboe BZX)
12.17 -0.08 (-0.65%) 02/21/25 [NASDAQ]
12.10 x 1 12.25 x 1
Post-market 12.04 -0.13 (-1.07%) 19:34 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
11.93
Day High
12.63
Open 12.61
Previous Close 12.25 12.25
Volume 4,448,800 4,448,800
Avg Vol 3,123,550 3,123,550
Stochastic %K 84.66% 84.66%
Weighted Alpha -54.32 -54.32
5-Day Change +2.53 (+26.24%) +2.53 (+26.24%)
52-Week Range 8.96 - 34.87 8.96 - 34.87
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,239,502
  • Shares Outstanding, K 101,849
  • Annual Sales, $ 36,280 K
  • Annual Income, $ -481,190 K
  • EBIT $ -538 M
  • EBITDA $ -529 M
  • 60-Month Beta 1.80
  • Price/Sales 27.14
  • Price/Cash Flow N/A
  • Price/Book 1.29

Options Overview Details

View History
  • Implied Volatility 94.59% ( +8.66%)
  • Historical Volatility 87.43%
  • IV Percentile 98%
  • IV Rank 77.24%
  • IV High 106.41% on 11/15/24
  • IV Low 54.50% on 08/21/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 3,924
  • Volume Avg (30-Day) 2,559
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 48,373
  • Open Int (30-Day) 41,613

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.32
  • Number of Estimates 11
  • High Estimate -0.86
  • Low Estimate -1.61
  • Prior Year -1.46
  • Growth Rate Est. (year over year) +9.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.96 +35.83%
on 02/12/25
Period Open: 9.94
12.84 -5.22%
on 02/20/25
+2.23 (+22.43%)
since 01/21/25
3-Month
8.96 +35.83%
on 02/12/25
Period Open: 13.80
16.01 -23.99%
on 12/02/24
-1.63 (-11.81%)
since 11/21/24
52-Week
8.96 +35.83%
on 02/12/25
Period Open: 26.88
34.87 -65.10%
on 02/29/24
-14.71 (-54.72%)
since 02/21/24

Most Recent Stories

More News
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

NTLA : 12.17 (-0.65%)
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

RPRX : 33.42 (+0.27%)
JNJ : 162.30 (+1.64%)
VRTX : 484.24 (+0.81%)
SNDX : 16.38 (+2.44%)
ABBV : 202.08 (+0.60%)
GERN : 2.57 (-2.28%)
RHHBY : 41.4200 (+0.66%)
PFE : 26.30 (+1.54%)
NTLA : 12.17 (-0.65%)
BMY : 55.83 (+0.07%)
BIIB : 140.64 (+2.60%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 12.17 (-0.65%)
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

ARKG : 26.94 (-5.67%)
IBB : 138.91 (-0.37%)
XBI : 91.70 (-1.10%)
NTLA : 12.17 (-0.65%)
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

NTLA : 12.17 (-0.65%)
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

NTLA : 12.17 (-0.65%)
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

CRSP : 47.91 (-5.00%)
VRTX : 484.24 (+0.81%)
REGN : 700.33 (+0.62%)
NTLA : 12.17 (-0.65%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 12.17 (-0.65%)
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA : 12.17 (-0.65%)
Intellia Therapeutics Announces FDA Grants RMAT Designation for CRISPR-Based Therapy nexiguran ziclumeran in Treating Hereditary ATTR Amyloidosis

Intellia Therapeutics receives FDA RMAT designation for nexiguran ziclumeran, a CRISPR therapy for hereditary ATTR amyloidosis.Quiver AI SummaryIntellia Therapeutics, Inc. announced that the U.S. FDA has...

NTLA : 12.17 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 13.26
2nd Resistance Point 12.94
1st Resistance Point 12.56
Last Price 12.17
1st Support Level 11.86
2nd Support Level 11.54
3rd Support Level 11.16

See More

52-Week High 34.87
Fibonacci 61.8% 24.97
Fibonacci 50% 21.91
Fibonacci 38.2% 18.86
Last Price 12.17
52-Week Low 8.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements